Alentis Therapeutics, the Claudin-1 (CLDN1) company, is a clinical stage biotechnology company on a mission to develop first-in-class antibodies and ADCs for CLDN1+ tumors and organ fibrosis. 

Alentis is pioneering a novel approach to modify and reverse the course of disease progression targeting CLDN1, a previously unexploited target that plays a key role in the pathology of tumors and fibrotic diseases across multiple organs. Alentis is the only company developing potential treatments for solid cancers and fibrosis targeting CLDN1. 

Alentis’ portfolio of anti-CLDN1 monoclonal antibodies includes a novel class of anti-cancer therapies designed to reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is highly promising for drug development as many cancers use the TME to build barriers that shield against immune system attacks. Alentis’ lead oncology asset, ALE.C04, is the first potential treatment to target CLDN1 in solid tumors.

In addition, Alentis’ pipeline includes first-in-class therapies designed to modify and reverse the course of advanced organ fibrosis. ALE.F02, which is currently in Phase 1 clinical trials, is designed to target pathological overexpression of CLDN1 outside of the tight junction to resolve and reverse organ fibrosis and is being investigated for the treatment of fibrotic disease in the kidney, lung, and liver. 

The company was founded in 2019 based on ground-breaking research in the laboratory of Prof. Thomas Baumert MD at the University of Strasbourg and the French National Institute of Health (Inserm). 

Alentis is headquartered in Basel’s pharma-biotech hub in Switzerland with a subsidiary for R&D in Strasbourg, France. For more information, please visit us at www.alentis.ch or write to: info@alentis.ch

Innosuisse

Pureos Bioventures

Schroder Adveq

BioMedPartners

Bpifrance

High-Tech Grunderfonds

Jeito Capital

Kinled Holding

Morningside Venture Investments

Novo Holdings

RA Capital Management

Schroders Capital

Alentis Therapeutics

Person Schema

CrUX Dataset

Gravatar Profiles

CrUX Top 50m

MediaElement.js

team.blue

Healthcare

Alberto Toso

Marketing and Product

Luigi Manenti

Brian Liu

Anna H. Chen

Neil Goldsmith

Rafaele Tordjman

Martin Münchbach

Jason Dinges

Naveed Siddiqi

Dina Chaya

Andrea Pellacani

Roberto Iacone

Rizwan Velji

Chief Business Officer

Tamas Schweighoffer

Thomas Baumert

Founder and Executive BoD

Greg Elson

Chief Technology Officer

Europe Companies (Top 10K)

Private Europe, Middle East, and Africa (EMEA) Companies (Top 10K)

Switzerland Companies With Fewer Than 1000 Employees (Top 10K)

Therapeutics Companies (Top 10K)

Alentis Therapeutics, the CLDN1 company, is a clinical-stage biotech investigating novel therapeutics for CLDN1+ cancers. Alentis is the pioneering business in the use of anti-CLDN1 ADCs and antibodies to modify and reverse the progression of certain diseases.

OrbiMed

Series D - Alentis Therapeutics

Grant - Alentis Therapeutics

Series C - Alentis Therapeutics

Series B - Alentis Therapeutics

Series A - Alentis Therapeutics

Basel

Basel-Stadt

Switzerland

Europe

Alentis Therapeutics: $181.4 Million (Series D) Raised For Advancing Clinical Development Of Anti-Claudin-1 ADCs

Swiss startup news

FDA approval and a key partnership to accelerate drug development

Metsera gets $215m for obesity trials, and other financings

French Tech Funding Wire November 15: OpenAirlines, Elicit Plant, Agicap & More!

Alentis Therapeutics raises USD 181.4M to develop new cancer and fibrosis treatments

Alentis Therapeutics–Bellevue: investment, 202411 financing round Series D totalling $181.4m incl existing + co-investor BB Pureos

ALE.C04 is a monoclonal antibody developed for Claudin-1 positive cancer indications, designed to selectively kill tumor cells and open the collagen barrier to enable immunotherapies and the immune system to attack the tumor.

Lixudebart (formerly ALE.F02) is a monoclonal antibody developed for liver, kidney, and lung fibrosis, designed to reverse fibrosis by blocking fibrotic signaling and opening the collagen barrier to preserve or restore organ function.

ALE.P02 is an antibody-drug conjugate (ADC) in preclinical development for Claudin-1 positive cancer indications, designed to deliver a tubulin inhibitor directly into tumor cells.

ALE.P03 is an antibody-drug conjugate (ADC) in preclinical development for Claudin-1 positive cancer indications, designed to deliver a topoisomerase I inhibitor directly into tumor cells.

United States

North America

Philippines

Asia

Bangladesh

Colombia

South America

Anoat Therapeutics is a biotech company focused on developing treatments for cancer and fibrosis.

Anoat Therapeutics

Triveni Bio is a biotech company specializing in cancer treatment and fibrosis reversal.

Triveni Bio

Attovia is a biotech company dedicated to developing innovative therapies for cancer and fibrosis.

Attovia

NorthSea Therapeutics is a biopharmaceutical company focused on developing treatments for liver diseases and fibrosis.

NorthSea Therapeutics

FoRx Therapeutics is a biotech company specializing in cancer treatment and fibrosis reversal.

FoRx Therapeutics

Galectin Therapeutics is a biopharmaceutical company focused on the development of therapies for fibrotic diseases, including cancer-related fibrosis.

Galectin Therapeutics

Travere Therapeutics is a biopharmaceutical company dedicated to developing treatments for rare and serious kidney diseases, including those related to cancer treatment.

Travere Therapeutics

Jnana Therapeutics is a biotech company focused on developing small molecule therapies for neurodegenerative diseases, including those associated with cancer treatment.

Jnana Therapeutics

SciClone Pharmaceuticals is a pharmaceutical company focused on developing and commercializing therapies for cancer and infectious diseases.

SciClone Pharmaceuticals

STADA is a pharmaceutical company specializing in the development and marketing of pharmaceutical products, including those for cancer treatment.

STADA

Faes Farma is a pharmaceutical company dedicated to the development and commercialization of pharmaceutical products, including those for cancer treatment.

Faes Farma

Aquestive Therapeutics is a pharmaceutical company focused on developing and commercializing treatments for central nervous system disorders, including those related to cancer treatment.

Aquestive Therapeutics

Alentis Therapeutics is a biotech company focused on developing treatments for cancer and reversing fibrosis by targeting Claudin-1, a protein involved in disease signaling and tumor cell growth.

news impact assignment basic	general	May 6, 2024 7:58 AM	0538731d
public peers	general	May 6, 2024 7:58 AM	d0479cb0
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	May 6, 2024 7:58 AM	9d470c14
company summary	general
signals	general
crunchbase trigger	general	Nov 25, 2024 9:06 AM	dc8c132b
crunchbase profile	general	Nov 25, 2024 11:40 AM	43467297
li profile	general	May 6, 2024 7:58 AM	0de0e3a0
translate crunchbase fundingrounds	general	Nov 25, 2024 2:09 PM	4aa44977
peers	general
news basic	general	May 6, 2024 7:58 AM	e7167c18
bundesanzeiger	filings
financials download nd	financials
private financials	financials

CH:ALENTIS

Alentis Therapeutics